Related references
Note: Only part of the references are listed.A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials
Martin D. Berger et al.
EUROPEAN JOURNAL OF CANCER (2020)
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Megan Li et al.
CLINICAL CANCER RESEARCH (2018)
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial
J. K. Mooi et al.
ANNALS OF ONCOLOGY (2018)
A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab
Martin D. Berger et al.
CLINICAL CANCER RESEARCH (2018)
Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials
Martin D. Berger et al.
EUROPEAN JOURNAL OF CANCER (2017)
Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer
Avelino Fraga et al.
BMC UROLOGY (2017)
Germline Genetic Variants in TEK, ANGPT1, ANGPT2, MMP9, FGF2 and VEGFA Are Associated with Pathologic Complete Response to Bevacizumab in Breast Cancer Patients
Issam Makhoul et al.
PLOS ONE (2017)
Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials
M. D. Berger et al.
ANNALS OF ONCOLOGY (2017)
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
A. J. Weickhardt et al.
BRITISH JOURNAL OF CANCER (2015)
Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer
Camille Sibertin-Blanc et al.
DIGESTIVE AND LIVER DISEASE (2015)
eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
Paola Ulivi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
VEGFA SNP rs2010963 is associated with vascular toxicity in recurrent glioblastomas and longer response to bevacizumab
Anna Luisa Di Stefano et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Genetic markers of bevacizumab-induced hypertension
Diether Lambrechts et al.
ANGIOGENESIS (2014)
Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy
Sanne de Haas et al.
ANGIOGENESIS (2014)
Evidence of Heterogeneity by Race/Ethnicity in Genetic Determinants of QT Interval
Amanda A. Seyerle et al.
EPIDEMIOLOGY (2014)
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer
Maressa A. Bruhn et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Clinical genotyping and efficacy outcomes: Exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer
Celine Pallaud et al.
LUNG CANCER (2014)
Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma
Chao Qin et al.
MUTAGENESIS (2014)
Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer
Byeong Seok Sohn et al.
ONCOLOGY (2014)
Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
D. W. Miles et al.
BRITISH JOURNAL OF CANCER (2013)
Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer
Sachi Morita et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Evanthia Galanis et al.
CLINICAL CANCER RESEARCH (2013)
Role of Endogenous Vascular Endothelial Growth Factor in Endothelium-Dependent Vasodilation in Humans
Anna M. J. Thijs et al.
HYPERTENSION (2013)
Markers of Response for the Antiangiogenic Agent Bevacizumab
Diether Lambrechts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
Fotios Loupakis et al.
PLOS ONE (2013)
The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer Results from the Nordic ACT trial
Torben Frostrup Hansen et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2012)
VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials
Diether Lambrechts et al.
LANCET ONCOLOGY (2012)
Signal Transduction by Vascular Endothelial Growth Factor Receptors
Sina Koch et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Developmental and Pathological Angiogenesis
Alicia S. Chung et al.
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 27 (2011)
Signal transduction by vascular endothelial growth factor receptors
Sina Koch et al.
BIOCHEMICAL JOURNAL (2011)
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients
Marie-Christine Etienne-Grimaldi et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer
Dylan M. Glubb et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacogenetic Angiogenesis Profiling for First-line Bevacizumab plus Oxaliplatin-Based Chemotherapy in Patients with Metastatic Colorectal Cancer
Armin Gerger et al.
CLINICAL CANCER RESEARCH (2011)
Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab
D. Lambrechts et al.
EUROPEAN JOURNAL OF CANCER (2011)
Allelic heterogeneity and more detailed analyses of known loci explain additional phenotypic variation and reveal complex patterns of association
Andrew R. Wood et al.
HUMAN MOLECULAR GENETICS (2011)
Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab
Vincenzo Formica et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2011)
Genetics of VEGF Serum Variation in Human Isolated Populations of Cilento: Importance of VEGF Polymorphisms
Daniela Ruggiero et al.
PLOS ONE (2011)
VEGF-460T→C polymorphism and its association with VEGF expression and outcome to FOLFOX-4 treatment in patients with colorectal carcinoma
M-H Chen et al.
PHARMACOGENOMICS JOURNAL (2011)
Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A. Meta-Analysis
Vishal Ranpura et al.
AMERICAN JOURNAL OF HYPERTENSION (2010)
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients
A. Abajo et al.
BRITISH JOURNAL OF CANCER (2010)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
Niall C. Tebbutt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib
Lokesh Jain et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
Adrian M. Jubb et al.
LANCET ONCOLOGY (2010)
Gene-environment-wide association studies: emerging approaches
Duncan Thomas
NATURE REVIEWS GENETICS (2010)
Genome-wide association studies in diverse populations
Noah A. Rosenberg et al.
NATURE REVIEWS GENETICS (2010)
The Role of Vascular Endothelial Growth Factor Genetic Variability in Cancer
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2009)
Vascular Endothelial Growth Factor Receptor 2 Controls Blood Pressure by Regulating Nitric Oxide Synthase Expression
Carie S. Facemire et al.
HYPERTENSION (2009)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
Leonard B. Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
VEGF inhibition and renal thrombotic microangiopathy
Vera Eremina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature
T Kamba et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2006)
Bevacizurnab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer
HI Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Association of VEGF genotype with mRNA level in colorectal adenocarcinomas
M Yamamori et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production
CJ Watson et al.
CYTOKINE (2000)
Share Paper
